**Active Pharmaceutical Ingredients (API):** approx. 60% of revenue
**Finished Pharmaceuticals:** approx. 25% of revenue
**Chemical Intermediates:** approx. 15% of revenue

**TOP 3 Markets:**

1. **China:** approx. 45%
2. **USA:** approx. 30%
3. **Europe:** approx. 15%

Zhejiang Tianyu Pharmaceutical Co., Ltd. generates the majority of its revenue from the sale of active pharmaceutical ingredients used in drug manufacturing. The domestic market of China is the largest sales market, followed by the USA and Europe, which are also significant markets for the company. These markets benefit from the strong demand for pharmaceutical products and the company's strategic partnerships in these regions.

**Production Sites:** Zhejiang, China

Zhejiang Tianyu Pharmaceutical Co., Ltd. mainly produces its products in the province of Zhejiang, China. The company has several production facilities there that specialize in the manufacturing of pharmaceutical ingredients. The strategic location in one of the most economically dynamic regions of China enables the company to produce and export efficiently.

In recent years, production capacities have been continuously expanded to meet the increasing demand and better serve international markets.

**Revenue growth:** 10.5% (2025)
**R&D investments:** 8% of revenue (2025)

Zhejiang Tianyu Pharmaceutical Co., Ltd. pursues a strategy that is heavily focused on research and development (R&D) to secure future growth. The company continuously invests a significant portion of its revenue in R&D to develop innovative pharmaceutical products and expand its product pipeline.

Another focus is on international expansion. The company aims to strengthen its presence in global markets, particularly in the USA and Europe, to benefit from the increasing demand for high-quality generics and specialized pharmaceutical products.

In addition, Zhejiang Tianyu relies on strategic partnerships and alliances with other pharmaceutical companies to leverage synergies and accelerate market access. This strategy is intended not only to promote growth but also to enhance the company's competitiveness in the global market.

**Main raw materials:** API intermediates, chemicals

**Import countries:** India, China (local), USA

Zhejiang Tianyu Pharmaceutical Co., Ltd. mainly imports active pharmaceutical ingredients (APIs) and intermediates required for drug manufacturing. India is a significant supplier of APIs due to its strong pharmaceutical industry. Additionally, the company sources special chemicals and raw materials from the USA needed for the research and development of new drugs.

Local procurement within China also plays an important role as the company benefits from the country's well-developed chemical industry to minimize costs and optimize supply chains.

**Market Share:** 8% (estimated 2026)
**R&D Investments:** 10% of revenue (2025)
**Export Share:** 40% of total revenue (2025)

Zhejiang Tianyu Pharmaceutical Co., Ltd. has gained a solid competitive advantage through its strong focus on research and development. With investments of around 10% of revenue in R&D, the company remains at the forefront of pharmaceutical innovations, helping it to introduce new and improved products to the market.

Another advantage is the high export share of 40% of total revenue, indicating a strong international presence and competitiveness. This enables the company to benefit from global market opportunities and compete against local and international rivals.

Additionally, the estimated market share of 8% strengthens Zhejiang Tianyu Pharmaceutical's position in the domestic market, reflecting an effective market strategy and strong customer loyalty. Together, these factors give the company a sustainable competitive edge in the industry.

**Institutional Investor Share:** 28% (2026, estimated)

**Insider Buys/Sells:** No significant transactions in the last year (2025)

The institutional investor share in Zhejiang Tianyu Pharmaceutical Co., Ltd. is estimated to be around 28%. This indicates a moderate interest of institutional investors in the company, suggesting a certain level of stability and trust in the management.

In 2025, there were no significant insider buys or sells, indicating that the management and other insiders do not currently expect any major changes in the company's valuation. This can be interpreted as a sign of a stable corporate situation.

**Market share of Zhejiang Tianyu Pharmaceutical Co., Ltd.:** Estimated 4-6% (2026)

**Top competitors and their market shares:**
1. **CSPC Pharmaceutical Group Limited:** 10-12%
2. **Hengrui Medicine:** 9-11%
3. **Sino Biopharmaceutical Limited:** 8-10%
4. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 7-9%
5. **Jiangsu Hengrui Pharmaceuticals Co., Ltd.:** 6-8%
6. **Zhejiang Tianyu Pharmaceutical Co., Ltd.:** 4-6%
7. **Huadong Medicine Co., Ltd.:** 3-5%
8. **Tasly Pharmaceutical Group Co., Ltd.:** 3-5%
9. **Shandong Buchang Pharmaceuticals Co., Ltd.:** 2-4%
10. **Yunnan Baiyao Group Co., Ltd.:** 2-4%

**Moat of Zhejiang Tianyu Pharmaceutical Co., Ltd.:**

Zhejiang Tianyu Pharmaceutical Co., Ltd. has a moderate moat, mainly based on its specialization in the production of active pharmaceutical ingredients (APIs) and its strong position in certain niche markets. The company benefits from long-standing customer relationships and an efficient production infrastructure.

Compared to larger competitors like CSPC Pharmaceutical Group and Hengrui Medicine, which have more extensive product portfolios and stronger research and development departments, the moat of Zhejiang Tianyu is less pronounced. These competitors often have better access to international markets and greater financial resources to invest in innovations.

Overall, Zhejiang Tianyu has a specific advantage in its niche, but larger companies are able to establish a more comprehensive moat through their broader market presence and stronger innovation capabilities.

**Revenue growth:** 8.5% (2025)
**Research and development ratio:** 12% of revenue (2025)
**Market share in API production:** 5% (2025, estimated)

Zhejiang Tianyu Pharmaceutical Co., Ltd. recorded a revenue growth of 8.5% in 2025. This indicates a solid business development, especially in the competitive pharmaceutical industry. The investment in research and development, accounting for 12% of revenue, demonstrates the company's commitment to developing innovative products and strengthening its market position.

The company holds an estimated 5% market share in the production of active pharmaceutical ingredients (API), indicating a strong market presence. These factors, combined with a strategic focus on research and development, could lead to positive long-term business growth.

Overall, Zhejiang Tianyu Pharmaceutical Co., Ltd. could present an attractive investment opportunity, especially for investors interested in a company that invests in research and development and has a strong market position in API production.

**Dividend Yield:** 2.5% (estimated for 2026)
**Dividend History:** Continuous payouts since 2018

Zhejiang Tianyu Pharmaceutical Co., Ltd. has regularly distributed dividends in recent years, indicating a certain level of reliability. The estimated dividend yield for 2026 is around 2.5%, based on the latest available data and payout trends from previous years.

The company has a solid financial foundation and demonstrates stable profitability, supporting its ability to make continuous dividend payments. However, investors should also keep an eye on the overall market conditions and specific company developments to better assess the future reliability of dividend payments.